The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients

A meta-analysis

Ying Huang, MM, Aizong Shen, MD

Abstract

Background: Programmed death receptor-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have been demonstrated to improve the prognosis of patients with advanced non-small cell lung cancer (NSCLC) compared with chemotherapy. However, there were still some non-responders. Thus, how to effectively screen the responder may be an important issue. Recent studies revealed the immune-related indicator, neutrophil-lymphocyte ratio (NLR), may predict the therapeutic effects of anti-PD1/PD-L1 antibodies; however, the results were controversial. This study was to re-evaluate the prognostic potential of NLR for NSCLC patients receiving PD1/PD-L1 inhibitors by performing a meta-analysis.

Methods: Eligible studies were identified by searching online databases of PubMed, EMBASE and Cochrane Library. The predictive values of NLR for overall survival, (OS), progression free survival (PFS) and overall response rate (ORR) were estimated by hazard ratio (HR) with 95% confidence interval (CI).

Results: Twenty-four studies involving 2196 patients were included. The pooled analysis demonstrated that elevated NLR before PD-1/PD-L1 inhibitor treatment was a predictor of poor OS (HR = 2.17; 95% CI: 1.64 – 2.87, P < .001), PFS (HR = 1.54; 95% CI: 1.34 – 1.78, P < .001) and low ORR (HR = 0.64; 95% CI: 0.44 – 0.95, P = .027) in NSCLC patients. Subgroup analysis revealed the predictive ability of NLR for OS and PFS was not changed by ethnicity, sample size, cut-off, HR source, study design or inhibitor type (except the combined anti-PD-L1 group); while its association with ORR was only significant when the cut-off value was less than 5 and the studies were prospectively designed.

Conclusion: Our findings suggest patients with lower NLR may benefit from the use of PD-1/PD-L1 inhibitors to prolong their survival period.

Abbreviations: CI = confidence interval, HR = hazard ratios, NLR = neutrophil-lymphocyte ratio, NSCLC = non-small cell lung cancer, OS = overall survival, ORR = overall response rate, PD-1 = programmed death receptor-1, PD-L1 = programmed death ligand 1, PFS = progression free survival.

Keywords: non-small cell lung cancer, programmed death receptor-1, programmed death ligand 1, neutrophil-lymphocyte ratio, prognosis, response rate
1. Introduction

Lung cancer is one of the most frequently seen malignant tumors worldwide, with an estimated 228,150 new cases diagnosed and causing 142,670 deaths in 2019 in the USA. Non-small cell lung cancer (NSCLC) is the major subtype of lung cancer, which accounts for approximately 80% of all lung cancer patients. Clinically, chemotherapy is recommended as the first-line treatment option for patients with advanced inoperable NSCLC. However, both of the response rate (less than 50%) and the 5-year overall survival (OS) rate (approximately 5%) of patients undergoing chemotherapy seem to be relatively low, indicating more effective drugs are necessary to be developed.

Recently, there is increasing evidence to indicate that immune evasion is a central hallmark of lung cancer. Activation of the program death-1 (PD-1)/program death-ligand 1 (PD-L1) pathway is an important mechanism to evade immune elimination of tumor cells. The binding of PD-1 with its ligand PD-L1 transmits a co-inhibitory signal for activated T-cells and then promotes T-cell exhaustion, ultimately preventing T-cell-mediated cellular cytotoxicity. NSCLC patients with high expression of PD-L1 and PD-1 were observed to have a tendency for shorter survival. These findings suggest inhibition of the expressions of PD-1 and PD-L1 may be potentially important approaches for the treatment of NSCLC. This theory has been demonstrated by some scholars via the use of monoclonal antibodies against PD-1 (nivolumab and pembrolizumab) or PD-L1 (atezolizumab, durvalumab and avelumab), with the response rate and OS respectively improving to 75% and 25%. However, there were still some patients who could not benefit from the use of PD-1/PD-L1 inhibitors. Therefore, it is indispensable to distinguish the responders from the non-responders to schedule cost-effective treatment strategy for them, in which identification of appropriate biomarkers may be the first problem required to be resolved.

Assay of peripheral blood counts (including neutrophils and lymphocytes) is the routine examination in clinic to assess the inflammatory and immune status of cancer patients before treatment. The elevated neutrophil-lymphocyte ratio (NLR) representing systemic inflammation was shown to be associated with poor prognosis in NSCLC patients, suggesting NLR may serve as a potential biomarker to predict the therapy outcomes of PD-1/PD-L1 inhibitors for NSCLC patients. This hypothesis has been proved by a meta-analysis performed by Cao et al., which showed that higher baseline NLR was associated with poor progression free survival (PFS) [10 studies: hazard ratios (HR) = 1.44; 95% confidence interval (CI) = 1.18 – 1.77; P < 0.05] and OS [8 studies: HR = 1.75; 95% CI: 1.33 – 2.30; P < 0.05] in patients with NSCLC after nivolumab treatment. The similar conclusion was also verified in NSCLC stratification of meta-analysis studies focusing on all cancer types (Tan et al. 4 articles; Sacdal et al. 3 articles; Xie et al. 6 articles). However, the literature size in these meta-analyses seemed to be small and abundant negative associations of NLR with OS or PFS were observed in the recent studies published in 2019 which were not included previously. Hereby, the prediction ability of NLR for the therapeutic effects of anti-PD1/PD-L1 antibodies in NSCLC patients remains inconclusive.

The objective of this meta-analysis was to re-evaluate the significance of NLR as a predictive factor in NSCLC patients receiving PD1/PD-L1 inhibitors based on 24 published evidences.

2. Materials and methods

This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis. Patient consent and ethical approval were waived since the present study only used published studies.

2.1. Search strategies

A systematic electronic search was conducted in the databases of PubMed, Embase and the Cochrane library on December 1, 2019. The following search terms were used: (“programmed death-1 receptor” OR “programmed death ligand-1” OR “PD-1 inhibitor” OR “PD-L1 inhibitor” OR “anti-PD-1 antibodies” OR “immune checkpoint inhibitors” OR “immunotherapy” OR “nivolumab” OR “pembrolizumab” OR “atezolizumab” “avelumab” OR “durvalumab”) AND (“neutrophil-to-lymphocyte ratio” OR “NLR” OR “neutrophil to lymphocyte ratio”). Furthermore, the references of eligible studies and previous reviews were hand-checked for additional articles.

2.2. Inclusion and exclusion criteria

Studies were considered eligible if they met the following inclusion criteria:

1. enrolled patients were histologically diagnosed with lung cancer;
2. patient received the PD1/PD-L1 inhibitor monotherapy;
3. the associations between NLR and therapeutic outcomes [such as OS, PFS and overall response rate (ORR)] were evaluated;
4. NLR was measured before PD1/PD-L1 inhibitor; and
5. HRs with corresponding 95% CIs could be directly collected or indirectly calculated from original data or Kaplan–Meier curves.

The exclusion criteria were as follows:

1. duplicate publication;
2. studies included the patients who received immune checkpoint inhibitors targeting cytotoxic T-lymphocyte–associated antigen 4 or underwent other therapeutic strategies concurrently;
3. studies focused on mixed cancer types;
4. studies did not analyze NLR value, but the derived or log-transformed NLR;
5. studies were not related to our topics;
6. case reports, reviews and non-human studies;
7. lack of sufficient data to estimate HRs and 95% CIs; and
8. non-English publications.

2.3. Data extraction and quality assessment

Two researchers independently extracted the following data from each study: first author’s name, publication year, country of origin, sample size, PD-1/PD-L1 inhibitor, study design, follow-up, NLR cut-off, the outcome measures, HR with 95% CI and their source. HRs and 95% CIs were preferentially extracted from their source. HRs and 95% CIs could be directly collected or indirectly calculated from original data or Kaplan–Meier curves.
The quality of included studies was assessed according to Newcastle-Ottawa Scale. Studies with a Newcastle-Ottawa Scale score greater than 7 were considered as the high-quality literatures.

### 2.4. Statistical analysis

All statistical analyses were carried out using STATA 13.0 (STATA Corporation, College Station, TX). The prediction potential of NLR for therapeutic outcomes of PD-1/PD-L1 inhibitors in NSCLC patients was evaluated by pooled HR and 95% CI. HR > 1 indicated poor OS, PFS and ORR in patients with a higher pretreatment NLR; HR < 1 implied high NLR predicted favorable therapeutic outcomes. Statistical difference was determined by using z test. Heterogeneity across studies was assessed by Cochrane Q and I² statistic tests. A random-effects model was adopted if significant heterogeneity was observed (P < .10 and I² > 50%); otherwise, a fixed-effects model was chosen. Subgroup analyses were performed by country, sample size, cut-off of NLR, HR source, study design and PD-1/PD-L1 inhibitors. Publication bias was examined using Egger linear regression test, followed by adjustment with the “trim and fill” algorithm. Sensitivity analysis was performed by omitting one study at a time to assess the robustness of the results. Significance levels were set at P < .05.

### 3. Results

#### 3.1. Literature search and study characteristics

A flowchart of the study inclusion process is shown in Figure 1. A total of 814 records were initially identified through electronic databases searching. Then, 314 studies were screened after the removal of duplicates. After reading titles and abstracts, 282
articles were excluded because they were either case reports (n = 4), meta/review (n = 10), studies investigating other cancers (n = 114), other drugs (n = 3), irrelevant topics (n = 115), without prognostic outcomes (n = 1) or non-human studies (n = 35). Full-text review further eliminated 8 studies since they did not report detailed data (n = 2), treatment drugs (n = 2) or directly analyze NLR (n = 4). Finally, 24 studies were included in this meta-analysis.[17–20,24–43]

The detailed characteristics of these 24 studies are presented in Table 1. These included studies were published from 2017 to 2020 and analyzed the treatment effects for advanced NSCLC patients from Japan (n = 9), USA (n = 4), Korea (n = 1), France (n = 1), Italy (n = 4), Canada (n = 1), Germany (n = 1), Czech (n = 1), Spain (n = 1) and China (n = 1). The immunotherapy agent was nivolumab in 16 studies; while in the remaining 8 studies, patients treated with pembrolizumab, atezolizumab or atezolizumab were enrolled as the whole. Five studies were prospectively designed, while the other 19 studies retrospectively reviewed the records of patients. The associations of NLR with primary endpoints (ORR, OS and PFS) were obtained from univariate analysis, multivariate analysis or Kaplan-Meier curve. The cut-off value of NLR was reported in most of the studies (23/24, 95.8%), with the range from 3 to 6. The quality assessment result suggested that all the included studies were of high quality (Table 1).

### Table 1

| Study   | Year  | Country | No.  | Age (yr) | Male sex | PD-1/PD-L1 inhibitor | Design | Follow-up | Cut-off | Outcome | HR/95%CI | NOS |
|---------|-------|---------|------|----------|----------|----------------------|--------|-----------|---------|---------|---------|-----|
| Bagley SJ | 2017  | USA     | 117  | 68 (70–84) | 80       | Nivolumab            | R      | Unclear   | 5       | OS, PFS (significant) | ORR (non-significant) | OS, PFS (M), ORR (U) | 8   |
| Ragado J | 2017  | Spain   | 40   | 67        | Unclear  | Nivolumab            | R      | Unclear   | 5       | OS, PFS (significant) | ORR (non-significant) | U    | 8   |
| Galetta D | 2017  | Italy   | 47   | 47 (40–83) | 41       | Nivolumab            | R      | Unclear   | 4       | PFS     | U       | 8   |
| Suh KJ  | 2018  | Korea   | 54   | Unclear   | 42       | Pembrolizumab        | R      | 26.2 mo   | 5       | OS, PFS, ORR (non-significant) | U (K-M estimated) | 8   |
| Shiroyama T | 2018 | Japan   | 201  | 68 (27–87) | 135      | Nivolumab            | R      | 12.4 mo   | 4       | PFS, ORR (significant) | U       | 8   |
| Khungar N | 2018  | USA     | 109  | 67 (45–90) | 56       | Nivolumab            | R      | 30 mo     | 5       | OS (non-significant) | U (K-M estimated) | 8   |
| Kiru T   | 2018  | Japan   | 19   | 41 (63–78) | 19       | Nivolumab            | R      | Unclear   | 5       | OS (significant) | ORR (non-significant) | U (K-M, estimated) | 8   |
| Takeh T  | 2018  | Japan   | 30   | 71 (54–83) | 19       | Nivolumab            | R      | 28 d      | 5       | PFS (non-significant) | U (K-M, estimated) | 8   |
| Nakaya A | 2018  | Japan   | 109  | 69 (45–54) | 77       | Nivolumab            | R      | 8.9 mo    | 3       | PFS (non-significant) | U (K-M, estimated) | 8   |
| Faschinetti F | 2018 | Italy   | 54   | 69 (43–85) | 45       | Nivolumab            | P      | 12.6 mo   | 4       | OS (significant) | ORR (significant) | GS (M), ORR (U) | 8   |
| Zer A   | 2018  | Canada  | 88   | 64 (31–81) | 43       | Unclear (mixed)      | P      | 5.3 mo    | 4       | OS (significant) | ORR (significant) | GS, ORR (U), K-M (directly obtained), ORR (M) | 9   |
| Park W   | 2018  | USA     | 159  | 68 (41–91) | 82       | Nivolumab            | R      | 11.5 mo   | 5       | OS, PFS (significant) | U       | 8   |
| Suvan M  | 2018  | Czech   | 120  | Unclear   | 71       | Nivolumab            | R      | Unclear   | 3.8     | OS (significant) | U (K-M estimated) | M    | 8   |
| Shiroyama T | 2018 | Japan   | 201  | 68 (27–87) | 135      | Pembrolizumab        | P      | 20.0 mo   | 5.9     | PFS (non-significant) | M       | 8   |
| Sojano AE | 2018  | USA     | 157  | 66 (27–87) | 83       | Pembrolizumab        | P      | 10.9 mo   | 5       | PFS (significant) | GS (M), ORR (U) | 8   |
| Fukui T  | 2019  | Japan   | 52   | 69 (46–83) | 37       | Pembrolizumab        | P      | 10.9 mo   | 5       | ORR (significant) | M       | 8   |
| Ichiki Y | 2019  | Japan   | 44   | 71 (42–91) | 37       | Pembrolizumab        | P      | 145 d     | Unclear | ORR (significant) | U       | 8   |
| Minami S | 2019  | Japan   | 76   | Unclear   | 49       | Pembrolizumab, pembrolizumab, atezolizumab | R      | Unclear   | 6       | OS, PFS (non-significant) | M       | 8   |
| Dusseler M | 2019 | France  | 59   | 60 (30–67) | 44       | Nivolumab            | R      | Unclear   | 5       | OS (non-significant) | ORR (non-significant) | U    | 8   |
| Passiglia F | 2019 | Italy   | 46   | 66 (51–90) | 32       | Pembrolizumab        | R      | 9.1 mo    | 3.3     | PFS (non-significant) | ORR (M) | 8   |
| Liu J    | 2019  | China   | 44   | 60 (63–74) | 33       | Pembrolizumab        | R      | 6.9 mo    | 3.07    | ORR (non-significant) | ORR (M) | 8   |
| Shige F  | 2019  | Japan   | 102  | 69 (42–96) | 73       | Pembrolizumab, pembrolizumab, atezolizumab | R      | 201 d     | 3.88    | ORR (non-significant) | ORR (M) | 8   |
| Paw A    | 2019  | Italy   | 184  | 67 (37–83) | 125      | Pembrolizumab, pembrolizumab, atezolizumab | P      | 56.3 mo   | 3       | OS, PFS (significant) | M       | 8   |
| Möller M | 2020  | Germany | 35   | 65 (24–85) | 19       | Pembrolizumab, pembrolizumab, atezolizumab | P      | 9.7 mo    | 5.2     | ORR (non-significant) | U (K-M, estimated) | 8   |

Cl = confidence intervals, HR = hazard ratio, K-M = Kaplan-Meier curve, M = multivariate analysis, NOS = Newcastle-Ottawa Scale, OS = overall survival, ORR = overall response rate, P = prospective, PD-1 = programmed death-1, PD-L1 = programmed death ligand 1, PFS = progression-free survival, R = retrospective, U = univariate analysis.

#### 3.2. The association between NLR and OS

Eighteen studies reported the association between pretreatment NLR and OS in NSCLC patients receiving PD-1/PD-L1 inhibitors. The heterogeneity test revealed significant heterogeneity existed among these studies ($I^2 = 79.2\%$, $P < .001$), so a random-effect model was used (Table 2). The pooled meta-analysis demonstrated that patients with an elevated NLR were associated with shorter OS after treatment with PD-1/PD-L1 inhibitor (HR = 2.17; 95% CI: 1.64 – 2.87, $P < .001$; Fig. 2). This conclusion was similar after stratified analyses, irrespective of ethnicity, sample size, cut-off, HR source, study design or PD-1/PD-L1 inhibitor type (Table 2).

#### 3.3. The association between NLR and PFS

Nineteen studies investigated the association between baseline NLR and PFS in NSCLC patients treated with anti-PD-1/PD-L1 antibodies. A random-effect model was chosen due to obvious heterogeneity present among the included studies ($I^2 = 78.7\%$, $P < .001$) (Table 3). The pooled meta-analysis implied that NSCLC patients with high pretreatment NLR had a 1.54-fold higher risk of poor PFS (95% CI: 1.34 – 1.78, $P < .001$; Fig. 3). Moreover, this significant prognostic value of NLR for PFS was not changed after subgroup analyses according to ethnicity, sample size, cut-off, HR source, study design or PD-1/PD-L1 inhibitor type except the combined anti-PD-L1 group (Table 3).
### Table 2
The association between NLR and OS in NSCLC patients receiving PD-1/PD-L1 inhibitors.

| Comparison                  | Studies | HR (95%CI)   | $P_z$-value | $I^2$ | $P_H$-value | Model |
|-----------------------------|---------|--------------|-------------|------|-------------|-------|
| Overall                     | 18      | 2.17 (1.64,2.87) | <.001      | 79.2 | <.001       | R     |
| Subgroup                    |         |              |             |      |             |       |
| Country                     |         |              |             |      |             |       |
| Asian                       | 7       | 2.45 (1.83,3.28) | <.001      | 14.7 | .318        | F     |
| Non-Asian                   | 11      | 1.95 (1.40,2.71) | <.001      | 80.5 | <.001       | R     |
| Sample size                 |         |              |             |      |             |       |
| <100                         | 11      | 2.63 (2.05,3.39) | <.001      | 27.9 | .179        | F     |
| >100                         | 7       | 1.72 (1.24,2.39) | <.001      | 78.7 | <.001       | R     |
| Cut-off                     |         |              |             |      |             |       |
| <5                           | 6       | 1.89 (1.22,2.92) | .004       | 75.8 | .001        | R     |
| $\geq$ 5                    | 11      | 2.21 (1.80,2.69) | <.001      | 34.4 | .123        | F     |
| HR source [1]               |         |              |             |      |             |       |
| M                            | 9       | 2.11 (1.44,3.09) | <.001      | 79.0 | <.001       | R     |
| U                            | 9       | 2.22 (1.77,2.73) | <.001      | 41.8 | .089        | F     |
| HR source [2]               |         |              |             |      |             |       |
| K-M estimated               | 4       | 2.07 (1.50,2.84) | <.001      | 1.0  | .387        | F     |
| Directly obtained           | 14      | 2.19 (1.57,3.05) | <.001      | 80.7 | <.001       | R     |
| Study design                |         |              |             |      |             |       |
| Retrospective               | 13      | 2.06 (1.46,2.87) | <.001      | 80.8 | <.001       | R     |
| Prospective                 | 5       | 2.30 (1.86,3.16) | <.001      | 0.0  | .669        | F     |
| PD-1/PD-L1 inhibitor [1]    |         |              |             |      |             |       |
| Single type                 | 10      | 2.33 (1.88,2.88) | <.001      | 48.5 | .042        | F     |
| Mixed                       | 8       | 1.83 (1.30,2.59) | .001       | 71.6 | .001        | R     |
| PD-1/PD-L1 inhibitor [2]    |         |              |             |      |             |       |
| Anti-PD-1                   | 15      | 2.30 (1.93,2.73) | <.001      | 25.7 | .171        | F     |
| Combined anti-PD-L1         | 3       | 1.11 (1.04,1.18) | .001       | 37.0 | .204        | F     |

CI = confidence interval, F = fixed-effects, HR = hazard ratio, M = multivariate analysis, NLR = neutrophil-lymphocyte ratio, NSCLC = non-small cell lung cancer, OS = overall survival, PD-1 = programmed death-1, PD-L1 = programmed death ligand 1, $P_z$ = $p$-value for association, $P_H$ = $p$-value for heterogeneity, R = random-effects, U = univariate analysis.

![Forest plots showing the association between NLR and overall survival in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors.](image-url)

Figure 2. Forest plots showing the association between NLR and overall survival in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors. HR, hazard ratio; CI, confidence interval; PD-1, programmed death receptor-1; PD-L1, programmed death ligand 1; NLR, neutrophil-lymphocyte ratio.
Table 3

The association between NLR and PFS in NSCLC patients receiving PD-1/PD-L1 inhibitors.

| Comparison       | Studies | HR (95%CI) | $P_z$-value | $I^2$ | $P_{H}$-value | Model |
|------------------|---------|------------|-------------|-------|---------------|-------|
| Overall          | 19      | 1.54 (1.34, 1.78) | <.001       | 78.7  | <.001         | R     |
| Subgroup         |         |            |             |       |               |       |
| Country          |         |            |             |       |               |       |
| Asian            | 10      | 1.61 (1.39, 1.85) | <.001       | 0.0   | .706          | F     |
| Non-Asian        | 9       | 1.45 (1.21, 1.73) | <.001       | 84.1  | <.001         | R     |
| Sample size      |         |            |             |       |               |       |
| <100             | 11      | 1.85 (1.37, 2.50) | <.001       | 75.4  | <.001         | R     |
| >100             | 8       | 1.45 (1.16, 1.82) | .001        | 78.3  | <.001         | R     |
| Cut-off          |         |            |             |       |               |       |
| <5               | 8       | 1.30 (1.11, 1.52) | .001        | 76.8  | <.001         | R     |
| ≥ 5              | 11      | 1.65 (1.44, 1.89) | <.001       | 43.8  | .059          | F     |
| HR source [1]    |         |            |             |       |               |       |
| M                | 9       | 1.45 (1.14, 1.84) | .003        | 73.1  | <.001         | R     |
| U                | 10      | 1.80 (1.38, 2.35) | <.001       | 77.2  | <.001         | R     |
| HR source [2]    |         |            |             |       |               |       |
| K-M estimated    | 4       | 2.22 (1.40, 3.52) | .001        | 0.0   | .848          | F     |
| Directly obtained| 15      | 1.49 (1.28, 1.73) | <.001       | 81.3  | <.001         | R     |
| Study design     |         |            |             |       |               |       |
| Retrospective    | 15      | 1.45 (1.24, 1.69) | <.001       | 76.2  | <.001         | R     |
| Prospective      | 4       | 1.73 (1.44, 2.07) | <.001       | 0.0   | .587          | F     |
| PD-1/PD-L1 inhibitor [1] | | | | | | |
| Single type      | 12      | 1.67 (1.35, 2.06) | <.001       | 73.1  | <.001         | R     |
| Mixed            | 7       | 1.49 (1.08, 2.05) | .015        | 74.1  | .001          | R     |
| PD-1/PD-L1 inhibitor [2] | | | | | | |
| Anti-PD-1        | 16      | 1.71 (1.42, 2.06) | <.001       | 69.8  | <.001         | R     |
| Combined anti-PD-L1 | 3   | 1.12 (0.81, 1.54) | .486        | 48.5  | .144          | F     |

CI = confidence interval; F = fixed-effects; HR = hazard ratio; M = multivariate analysis; NLR = neutrophil-lymphocyte ratio; NSCLC = non-small cell lung cancer; PD-1 = programmed death receptor-1; PD-L1 = programmed death ligand 1; PFS = progression free survival; $P_z$ = p-value for heterogeneity; $P_{H}$ = p-value for association; R = random-effects; U = univariate analysis.

Figure 3. Forest plots showing the association between NLR and progression-free survival in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors. HR, hazard ratio; CI, confidence interval; PD-1, programmed death receptor-1; PD-L1, programmed death ligand 1; NLR, neutrophil-lymphocyte ratio.
3.4. The association between NLR and ORR

As shown in Table 4, the random-effect model was used for exploring the association between NLR and ORR because of significant heterogeneity among 6 included studies. Overall, the meta-analysis results showed elevated NLR contributed to a lower ORR for PD-1/PD-L1 inhibitors in NSCLC patients (HR = 0.64; 95% CI: 0.44 – 0.95, P = .027; Fig. 4). This significant result was only observed in subgroups with cut-off < 5 (HR = 0.38; 95% CI: 0.25 – 0.59, P < .001) and prospective design (HR = 0.32; 95% CI: 0.17 – 0.60, P < .001) (Table 4).

3.5. Publication bias and sensitivity analyses

Publication bias analysis showed that no evidence of publication bias was observed in the analysis of ORR, indicating the results were reliable (P = .051). There was significant publication bias for OS (P < 0.001) and PFS (P < .001), which were then corrected by the trim and fill method. However, the results still showed elevated NLR was a predictor for unfavorable OS (HR = 1.29; 95% CI: 1.00 – 1.68, P < .001) and PFS (HR = 1.19; 95% CI: 1.03 – 1.37, P < .001). The sensitivity analysis also proved that no individual study influenced the summary effects on OS and PFS, also suggesting the robustness of the results for these 2 prognostic outcomes (Fig. 5).

Table 4
The association between NLR and ORR in NSCLC patients receiving PD-1/PD-L1 inhibitors.

| Comparison                      | Studies | HR (95%CI)       | P<value | I²     | P_H-value | Model |
|---------------------------------|---------|------------------|---------|--------|-----------|-------|
| Overall                         | 6       | 0.64 (0.44,0.95) | .027    | 67.6   | .009      | R     |
| Subgroup                        |         |                  |         |        |           |       |
| Country                         |         |                  |         |        |           |       |
| Asian                           | 2       | 0.68 (0.32,1.48) | .332    | 83.7   | .013      | R     |
| Non-Asian                       | 4       | 0.58 (0.32,1.07) | .079    | 64.3   | .038      | R     |
| Sample size                     |         |                  |         |        |           |       |
| <100                            | 4       | 0.68 (0.41,1.07) | .092    | 71.9   | .014      | R     |
| >100                            | 2       | 0.60 (0.30,1.17) | .136    | 50.8   | .154      | R     |
| Cut-off                         |         |                  |         |        |           |       |
| <5                              | 3       | 0.38 (0.25,0.59) | <.001   | 0.0    | .586      | F     |
| ≥ 5                             | 3       | 0.95 (0.78,1.16) | .666    | 0.0    | .952      | F     |
| HR source                       |         |                  |         |        |           |       |
| M                               | 1       | 0.40 (0.16,1.01) | .052    | -      | -         | R     |
| U                               | 5       | 0.68 (0.46,1.03) | .068    | 69.5   | .011      | F     |
| Study design                    |         |                  |         |        |           |       |
| Retrospective                   | 4       | 0.81 (0.59,1.11) | .195    | 51.7   | .102      | F     |
| Prospective                     | 2       | 0.32 (0.17,0.60) | <.001   | 0.0    | .479      | R     |
| PD-1/PD-L1 inhibitor            |         |                  |         |        |           |       |
| Single type                     | 4       | 0.58 (0.33,1.02) | .058    | 68.2   | .024      | R     |
| Mixed                           | 2       | 0.70 (0.30,1.62) | .404    | 69.6   | .070      | R     |

CI = confidence interval, F = fixed-effects, HR = hazard ratio, M = multivariate analysis, NLR = neutrophil-lymphocyte ratio, NSCLC = non-small cell lung cancer, ORR = overall response rate, PD-1 = programmed death-1, PD-L1 = programmed death ligand 1, Pz_p-value for heterogeneity, Pz_p-value for association, R = random-effects, U = univariate analysis.
4. Discussion

Although there were meta-analyses to investigate the prognostic value of NLR for anti-PD-1/PD-L1 treatment in NSCLC patients,\textsuperscript{[13–16]} their sample size was relatively small (≤ 10). In the present study, a total of 24 publications involving 2196 patients were included to perform an updated meta-analysis. In line with previous meta-analyses, our pooled analysis validated that elevated NLR before PD-1/PD-L1 inhibitor treatment was a predictor of poor OS\textsuperscript{[13,14,16]} and PFS\textsuperscript{[13–16]} in NSCLC patients.
demonstrating NLR may be a promising biomarker to evaluate the prognostic outcome after anti-PD-1/PD-L1 antibody treatment. Furthermore, subgroup analysis was also conducted. However, different from the analysis results of Cao et al. in small sample size,[13] which showed only NLR ≥ 5 could predict PFS and OS, but not NLR < 5; NLR could predict PFS for American, not the Asian, our study indicated the associations of NLR for OS and PFS were still significant regardless of ethnicity or cut-off. These findings further reveal the necessity of our updated meta-analysis in order to achieve more reliable conclusions. Some subgroups were newly assessed for patients based on HR source, study design or inhibitor type. Most of them were also significant, except combined anti-PD-L1 (atezolizumab) subgroup for PFS. More interesting, high NLR was also proved to be associated with lower ORR, especially when the cut-off value was set to be less than 5 and the studies were prospectively designed. This conclusion was, for the first time, reported in our study, although the data were collected in the study of Cao et al.[13] These results may enrich the evidence to indicate the importance to detect NLR before the use of PD-1/PD-L1 inhibitors.

The prognostic potential of NLR for patients with PD-1/PD-L1 inhibitor treatment may be attributed to the correlation between neutrophil/lymphocyte and PD-1/PD-L1.[44] It was reported that patients with NSCLC showed a significantly higher neutrophil infiltration, but decreased CD3⁺/CD8⁺ T-cell infiltration.[45] Tumour-derived granulocyte colony stimulating factor activated neutrophils[46–48] and induced PD-L1 expression on neutrophils.[49] The activated neutrophils could suppress T cell proliferation and cytotoxic activity via binding of PD-L1 on the surface of neutrophils to PD-1 on T cells,[49–52] which may be beneficial for tumor immune evasion and malignant growth, ultimately leading to reduced survival of cancer patients.[49] The combined application of cytotoxic T lymphocytes and PD-1 inhibitor significantly decreased tumor volume and tumor weight in model mice, but promoted tumor necrosis and apoptosis compared with PD-1 inhibitor alone and blank control groups.[53] Thus, the presence of high NLR in lung cancer antagonized the therapeutic effects of PD-1/PD-L1 antibodies and resulted in the treatment failure.[54] The fact that high NLR could not predict the poor PFS for some patients receiving atezolizumab may be ascribed to their low PD-L1 expression (possible having other ligands[55]) on neutrophils.[50]

Several limitations should be considered in this study. First, most of included studies were retrospective which may introduce unavoidable bias in patient selection and data collection. Second, although the scale of our included literatures has been relative large, some potential outcomes (such as adverse events[8,13,25,51]) related with PD-1/PD-L1 inhibitor treatment remains rarely reported and the meta-analysis for it could not be assessed; while the reducing the complications was also an important advantage of PD-1/PD-L1 inhibitor compared with chemothera-py.[50] Third, the cut-off value of NLR varied widely in different studies, which influenced the clinical generalization. Fourth, most of the studies focused on the prognostic ability of NLR for patients undergoing anti-PD-1 (nivolumab and pembrolizumab). The role of NLR in predicting outcomes for anti-PD-L1 (atezolizumab, durvalumab and avelumab) monotherapy needed further investigation because the therapeutic effects of anti-PD-L1 and anti-PD1 antibodies seemed to be different.[55,57] Fifth, the prognostic values of post-treatment NLR for NSCLC patients treated with PD-1/PD-L1 inhibitors were also worth investigating in the future, especially for PFS.[13,25,27]

5. Conclusion
This meta-analysis demonstrated that NLR may serve as a potential biomarker to predict the treatment outcomes of PD-1/ PD-L1 inhibitors for NSCLC cancer patients. Only patients with lower NLR may benefit from the use of PD-1/PD-L1 inhibitors to prolong their survival period.

Author contributions
Conceptualization: Ying Huang, Aizong Shen.
Data curation: Ying Huang.
Formal analysis: Ying Huang, Aizong Shen.
Methodology: Ying Huang.
Writing – original draft: Ying Huang.
Writing – review & editing: Aizong Shen.

References
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.
[2] Kelly RJ, Shepherd FA, Krivoshik A, et al. A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage III/IV non-small-cell lung cancer. Ann Oncol 2019;30:1127–33.
[3] Bittoni MA, Arunachalam A, Li H, et al. Real-world treatment patterns, overall survival, and occurrence of adverse events associated with first-line therapies for Medicare patients 65 years and older with advanced non-small-cell lung cancer: a retrospective study. Clin Lung Cancer 2018;19:e629–35.
[4] Mu CY, Huang JA, Chen Y, et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2013;28:682–8.
[5] Qin A, Coffey DG, Warren EH, et al. Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Med 2019;8:5256–78.
[6] Waki K, Yamada T, Yoshiyama K, et al. PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. Cancer Sci 2014;105:1229–35.
[7] Ji M, Liu Y, Li Q, et al. PD-1/PD-L1 expression in NSCLC patients and its correlation with EGFR/KRAS mutations. Cancer Biol Ther 2016;17:407–13.
[8] Santini FC, Hellmann MD. PD-1/PD-L1 axis in lung cancer. Cancer J 2018;24:15–9.
[9]Gettner S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol 2018;36:1675–84.
[10]Vrankar M, Stancic K. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. Radiol Oncol 2018;52:281–8.
[11]Topalian SL, Hodi FS, Brahmer JR, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol 2019.
[12]Huang Q, Diao P, Li CL, et al. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer. Medicine 2020;99:e18607.
[13]Cao D, Xu H, Xu X, et al. A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies. Oncology 2018;87:1507262.
[14]Tan Q, Liu S, Liang C, et al. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: a meta-analysis. Thorac Cancer 2018;9:1220–30.
[15]Sacdanal DB, Lucero JA, Sacdanal DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther 2018;11:953–65.
[16]Xie X, Liu J, Yang H, et al. Prognostic value of baseline neutrophil-to-lymphocyte ratio in outcome of immune checkpoint inhibitors. Cancer Invest 2019;37:265–74.
[17] Minami S, Ibara S, Ikuta S, et al. Gustave Roussy immune score and Royal Marsden hospital prognostic score are biomarkers of immune-checkpoint inhibitor for non-small cell lung cancer. World J Oncol 2019;10:90–100.

[18] Dusselier M, Delache E, Delcourt N, et al. Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers. PLoS One 2019;14:e0219060.

[19] Passiglia F, Galvano A, Castiglia M, et al. Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. Ther Adv Med Oncol 2019;11.

[20] Shoji F, Takeoka H, Kozuma Y, et al. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer 2019;136:45–51.

[21] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.

[22] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.

[23] Peters JL, Sutton AJ, Jones DR, et al. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med 2007;26:4544–62.

[24] Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 2017;106 (Complete):1–7.

[25] Suh KJ, Kim SH, Kim YJ, et al. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small-cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother 2018;67:459–70.

[26] Fukui T, Okuma Y, Nakahara Y, et al. Activity of neutrophil and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non-small cell lung cancer: a prospective observational study. Clin Lung Cancer 2018;20:511–20.

[27] Shiroyama T, Suzuki H, Tamiya M, et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med 2018;7:13–20.

[28] Ichiki Y, Taira A, Chikashii Y, et al. Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors. J Thorac Dis 2019;11:1117–23.

[29] Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal 2019;33:e22964.

[30] Khunger M, Patil PD, Khunger A, et al. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS One 2018;13:e0197743.

[31] Takeda T, Takeuchi M, Saitoh M, et al. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer. Thorac Cancer 2018;9:1291–9.

[32] Kiru T, Yamamoto M, Nagano T, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. Plos One 2018;13:e0193018.

[33] Nakaya A, Kusada T, Yoshida H, et al. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int J Clin Oncol 2018;23:634–40.

[34] Francesco F, Michele V, Sebastiano B, et al. Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab. Immunotherapy 2018;10:681–94.

[35] Zer A, Sung MR, Walia P, et al. Correlation of neutrophil-to-lymphocyte ratio (NLR) and absolute neutrophil count (ANC) with outcomes with PD-1 axis inhibitors in patients with advanced non-small cell lung cancer (NSCLC). Clin Lung Cancer 2018;19.

[36] Möller M, Turzer S, Schütte W, et al. Blood immune cell biomarkers in patient with lung cancer undergoing treatment with checkpoint blockade. J Immunother 2020;43:57–66.

[37] Pavan A, Calvetti L, Dal Maso A, et al. Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Oncologist 2019;24:1128–36.

[38] Park W, Kwon D, Saravia D, et al. Developing a predictive model for clinical outcomes of advanced non-small cell lung cancer patients treated with nivolumab. Clin Lung Cancer 2018;19:820–8.e4.

[39] Svaton M, Zemanova M, Skrickova J, et al. Chronic inflammation as a potential predictive factor of Nivolumab therapy in non-small cell lung cancer. Anticancer Res 2018;38:6771–82.

[40] Shiroyama T, Suzuki H, Tamiya M, et al. Clinical characteristics of liver metastasis in Nivolumab-treated patients with non-small cell lung cancer. Anticancer Res 2018;38:4723–9.

[41] Soyanne AE, Dholaria B, Marin-Acevedo JA, et al. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell Lung Cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer 2018;6:129.

[42] Rogado J, Fenor De La Maza MA, Pacheco-Barcia V, et al. Are inflammatory markers predictive of nivolumab efficacy in advanced non-small-cell lung cancer (NSCLC)? J Thorac Oncol 2017;12:SS2108–9.

[43] Galetta D, Logroscino AF, Missino A, et al. P1.02c-085 neutrophil/lymphocyte ratio in advanced non-small cell lung cancer: correlation with prognosis and response to Anti-PD1 therapy. J Thorac Oncol 2017;12:SS1329–30.

[44] Jiang C, Cao S, Li N, et al. PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer. Cancer Cell Int 2019;19:233.

[45] Mitchell KG, Diao L, Karpinets T, et al. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. J Immunother Cancer 2020;8:e000405.

[46] Dwivedi P, Greis KD. Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. Exp Hematol 2017;46:9–20.

[47] Dwivedi P, Muench DE, Wagner M, et al. Time resolved quantitative phospho-tyrosine analysis reveals Bruton’s Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors 2018;33:75–87.

[48] Dwivedi P, Muench DE. Phospho serine and threonine analysis of normal and mutated granulocyte colony stimulating factor receptors 2019;6:21.

[49] Wang TT, Zhao YL, Peng LS, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut 2017;66:1900–11.

[50] Bowers NL, Helton ES, Huijbrechts RPH, et al. Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/ PD-L1 pathway. Plos Pathogens 2014;10:e1003993.

[51] Akbay EA, Koyama S, Liu Y, et al. Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade. J Thorac Oncol 2017;12:1268.

[52] He G, Zhang H, Zhou J, et al. Pertumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2015;34:141.

[53] Zhang X, Hu F, Li C, et al. OCT4KSOX2-specific cytotoxic T lymphocytes plus programmed cell death protein 1 inhibitor presented with synergistic effect on killing lung cancer stem-like cells in vitro and treating drug-resistant lung cancer mice in vivo. J Cell Physiol 2019;234:6758–68.

[54] Kargar J, Zhu X, Zhang H, et al. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight 2019;4.

[55] Pillai RN, Behera M, Oworkokey TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature 2018;124:271–7.

[56] Nishijima TF, Shachar SS, Nyrop KA, et al. Safety and tolerability of PD-L1 antagonists in lung cancer patients with advanced non-small cell lung cancer treated with nivolumab. J Immunother Cancer 2019;7:68.

[57] De Sousa Linhares A, Battin C, Jutz S, et al. Neutrophils plus programmed cell death protein 1 inhibitor presented with synergistic effect on killing lung cancer stem-like cells in vitro and treating drug-resistant lung cancer mice in vivo. J Cell Physiol 2019;234:6758–68.

[58] Kargar J, Zhu X, Zhang H, et al. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight 2019;4.

[59] Pillai RN, Behera M, Oworkokey TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature 2018;124:271–7.

[60] Nishijima TF, Shachar SS, Nyrop KA, et al. Safety and tolerability of PD-L1 antagonists in lung cancer patients with advanced non-small cell lung cancer treated with nivolumab. J Immunother Cancer 2019;7:68.